| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
4
| Verstandig Grant (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| Gandhi Leena (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| Yao Zhengbin (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| Roemer Alan S. (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| BARER SOL J (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| D'Angio Paul (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 07/07/2023 |
4
| Bertram Timothy (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 44,983 options to buy
@ $0.29, valued at
$13k
|
|
| 05/18/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
4
| BARER SOL J (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Bought 400,000 shares
@ $0.4103, valued at
$164.1k
|
|
| 03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/29/2022 |
4
| Jones Kristi (President and CEO) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 296,700 shares
@ $0 |
|
| 11/25/2022 |
4
| Trainer John (CFO) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 125,200 shares
@ $0 |
|
| 11/25/2022 |
4
| OELKE MATHIAS (Chief Science Officer) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 126,100 shares
@ $0 |
|
| 11/17/2022 |
4
| BARER SOL J (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Bought 75,000 shares
@ $0.4789, valued at
$35.9k
Bought 125,000 shares
@ $0.4824, valued at
$60.3k
|
|
| 10/28/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/15/2022 |
4
| D'Angio Paul (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 61,678 options to buy
@ $1.82, valued at
$112.3k
|
|
| 06/15/2022 |
4
| Roemer Alan S. (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 61,678 options to buy
@ $1.82, valued at
$112.3k
|
|
| 06/15/2022 |
4
| Verstandig Grant (Director) has filed a Form 4 on NexImmune, Inc.|
Txns:
| Granted 61,678 options to buy
@ $1.82, valued at
$112.3k
|
|
|